{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:55:45Z","timestamp":1781841345225,"version":"3.54.5"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2018,10,17]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Ponatinib is a third generation kinase inhibitor designed to overcome the gatekeeper T315I\nmutation. In different trials this drug showed inhibitory activity against native BCR-ABL1 kinase and\nseveral ABL1 mutations. For this reason, ponatinib is currently indicated for the treatment of chronic\nmyeloid leukaemia (CML) in every phase of disease resistant and\/or intolerant to dasatinib and\nnilotinib and for whom imatinib is not indicated anymore or for patients with T315I mutation. The drug\nis also indicated for Ph+ acute lymphoblastic leukaemia (ALL). Ponatinib was temporarily suspended\nin 2013 for the occurrence of cardiovascular thrombotic events. Since then, different investigators analyzed\nbaseline characteristics of patient candidates for ponatinib, especially cardiovascular profile, in\norder to describe general management recommendations in this setting.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title\/>\n<jats:p> \nIn this review, clinical trials data about the use of ponatinib in CML and Ph+ ALL patients will be\ndiscussed. It will be focused also about the safety and tolerability profile of the drug and future perspectives\nof employment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568009617666171002142659","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T09:58:28Z","timestamp":1507111108000},"page":"847-856","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Ponatinib: A Review of Efficacy and Safety"],"prefix":"10.2174","volume":"18","author":[{"given":"Fulvio","family":"Massaro","sequence":"first","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Molica","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/156070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/156070\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/156070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T16:05:49Z","timestamp":1609257949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/156070\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,10,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009617666171002142659","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}